[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631068":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":10,"locations":11,"responsibleParty":30,"collaborators":10,"id":32,"slug":10,"hasResults":33,"nctId":34,"briefTitle":35,"officialTitle":36,"acronym":10,"eligibilityCriteria":37,"healthyVolunteers":38,"sex":39,"minAge":40,"maxAge":10,"enrollmentInfo":41,"targetDuration":10,"studyType":44,"phases":10,"briefSummary":45,"conditions":46,"keywords":48,"overallStatus":14,"whyStopped":10,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":58},{"fullName":5,"class":6},"Glyance","INDUSTRY",[8],{"label":9,"type":10,"description":10,"interventionNames":10},"Subjects over 18 years old, willing to undergo non-surgical aesthetic procedures with AnGelHA 2",null,[12],{"facility":13,"status":14,"city":15,"state":16,"zip":17,"country":16,"cosmosGeoPoint":18,"geoPoint":23,"contacts":24},"Glyance Ltd","RECRUITING","Lod","Israel","7152026",{"type":19,"coordinates":20},"Point",[21,22],34.8903,31.9467,{"lat":22,"lon":21},[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Rachel Shemesh","CONTACT","+972535514894","rachel@axecium.com",{"type":31,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100631068",false,"NCT07495865","Post-market Clinical Follow-up (PMCF) Study of Safety and Performance of 502-01 AnGelHA 2","A Prospective, Open-label, Non-interventional Post-market Study Evaluating the Performance and Safety of AnGelHA 2 Filler for Correcting Moderate to Severe Wrinkles and Folds and Facial Contour Remodeling in Routine Clinical Use.","Inclusion Criteria:\n\n* Men or women of any race, 18 years of age or older.\n* Able to read, understand and sign informed consent.\n\nExclusion Criteria:\n\n* Pregnant or lactating women (contraindications as per IFU).\n* Having received prior dermal filler injections in the six months preceding the study.\n* Previously treated with semi-permanent or permanent filler in the intended injection area.\n* Presenting with a cutaneous disorder, inflammation or infection near to the treatment area.\n* Known hypersensitivity to lidocaine and\u002For lidocaine HCl or hyaluronic acid.\n* Metabolic or endocrine uncontrolled disease, anaphylaxis, severe allergies or uncontrolled immune disorder.\n* Undergoing or planning to undergo peeling treatment or laser-\u002Fultrasound-based treatment within 3 weeks before or after injection.\n* Have received anti-coagulation, anti-platelet, or thrombolytic medications (e.g., warfarin), anti- inflammatory drugs (NSAIDs such as aspirin, ibuprofen), or other substances known to prolong time of coagulation from a week before treatment. A wash-out period of a week is allowed.\n* Subject, who has a condition or is in Fuse",true,"ALL","18 Years",{"count":42,"type":43},87,"ESTIMATED","OBSERVATIONAL","Post-market clinical follow-up (PMCF) investigation to evaluate the performance and safety of AnGelHA 2 filler for the correction of moderate to severe wrinkles and folds and facial contour remodeling, in a routine clinical setting.",[47],"Wrinkles",[47],"2026-05-26",{"date":51,"type":52},"2026-05-28","ACTUAL",{"date":54,"type":52},"2026-02-08",{"date":56,"type":43},"2027-03-12",{"name":5,"class":6},1]